# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potentia...
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, Augu...
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...
Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024
Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 pri...